The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Treatment of Infections Due to MDR Gram-Negative Bacteria
Open accessAbstract
The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in critically ill patients presents many challenges. Since an effective treatment should be administered as soon as possible, resistance to many antimicrobial classes almost invariably reduces the probability of adequate empirical coverage, with possible unfavorable consequences. In this light, readily available patient’s medical history and updated information about the local microbiological epidemiology remain critical for defining the baseline risk of MDR-GNB infections and firmly guiding empirical treatment choices, with the aim of avoiding both undertreatment and overtreatment. Rapid diagnostics and efficient laboratory workflows are also of paramount importance both for anticipating diagnosis and for rapidly narrowing the antimicrobial spectrum, with de-escalation purposes and in line with antimicrobial stewardship principles. Carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii are being reported with increasing frequencies worldwide, although with important variability across regions, hospitals and even single wards. In the past few years, new treatment options, such as ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, and plazomicin have become available, and others will become soon, which have provide some much awaited resources for effectively counteracting severe infections due to these organisms. However, their optimal use should be guaranteed in the long term, for delaying as much as possible the emergence and diffusion of resistance to novel agents. Despite important progresses, PK/PD optimization of dosages and treatment duration in critically ill patients has still some areas of uncertainty requiring further study, that should take into account also resistance selection as a major endpoint. Treatment of severe MDR-GNB infections in critically ill patients in the near future will require an expert and complex clinical reasoning, of course taking into account the peculiar characteristics of the target population, but also the need for adequate empirical coverage and the more and more specific enzyme-level activity of novel antimicrobials with respect to the different resistance mechanisms of MDR-GNB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Self-citationTsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citationGaronzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Paul, M., Daikos, G. L., Durante-Mangoni, E., Yahav, D., Carmeli, Y., Benattar, Y. D., Skiada, A., Andini, R., Eliakim-Raz, N., Nutman, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30099-9 · Cited by 623
Kadri, S. S., Adjemian, J., Lai, Y. L., Spaulding, A. B., Ricotta, E., Prevots, D. R., Palmore, T. N., Rhee, C., Klompas, M., Dekker, J. P., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy378 · Cited by 605
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa
Srinivas, N., Jetter, P., Ueberbacher, B. J., Werneburg, M., Zerbe, K., Steinmann, J., Van der Meijden, B., Bernardini, F., Lederer, A., Dias, R. L. A., et al. (2010) · Science · doi:10.1126/science.1182749 · Cited by 554
Tumbarello, M., Trecarichi, E. M., De Rosa, F. G., Giannella, M., Giacobbe, D. R., Bassetti, M., Losito, A. R., Bartoletti, M., Del Bono, V., Corcione, S., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv086 · Cited by 511
Self-citationShields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 495
Shields, R. K., Chen, L., Cheng, S., Chavda, K. D., Press, E. G., Snyder, A., Pandey, R., Doi, Y., Kreiswirth, B. N., Nguyen, M. H., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02097-16 · Cited by 484
Wunderink, R. G., Giamarellos-Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vazquez, J., Cornely, O. A., Solomkin, J., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 461
Self-citationMotsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420
Carmeli, Y., Armstrong, J., Laud, P. J., Newell, P., Stone, G., Wardman, A., & Gasink, L. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30004-4 · Cited by 417
Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., Bassetti, M., Malacarne, P., Petrosillo, N., Galdieri, N., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit253 · Cited by 405
Self-citationWagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G., & Darouiche, R. O. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62220-0 · Cited by 388
Tumbarello, M., Trecarichi, E. M., Corona, A., De Rosa, F. G., Bassetti, M., Mussini, C., Menichetti, F., Viscoli, C., Campoli, C., Venditti, M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy492 · Cited by 354
Self-citationIto, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Kaye, K. S., Bhowmick, T., Metallidis, S., Bleasdale, S. C., Sagan, O. S., Stus, V., Vazquez, J., Zaitsev, V., Bidair, M., Chorvat, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.0438 · Cited by 314
Pankey, G. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki248 · Cited by 301
Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2016.4237 · Cited by 276
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
Sirijatuphat, R., & Thamlikitkul, V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02435-13 · Cited by 235
Sutcliffe, J. A., O'Brien, W., Fyfe, C., & Grossman, T. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01288-13 · Cited by 235
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Zusman, O., Avni, T., Leibovici, L., Adler, A., Friberg, L., Stergiopoulou, T., Carmeli, Y., & Paul, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01230-13 · Cited by 233
Solomkin, J. S., Gardovskis, J., Lawrence, K., Montravers, P., Sway, A., Evans, D., & Tsai, L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1029 · Cited by 222
Pontikis, K., Karaiskos, I., Bastani, S., Dimopoulos, G., Kalogirou, M., Katsiari, M., Oikonomou, A., Poulakou, G., Roilides, E., & Giamarellou, H. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.09.010 · Cited by 220
Once-Daily Plazomicin for Complicated Urinary Tract Infections
Wagenlehner, F. M. E., Cloutier, D. J., Komirenko, A. S., Cebrik, D. S., Krause, K. M., Keepers, T. R., Connolly, L. E., Miller, L. G., Friedland, I., & Dwyer, J. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1801467 · Cited by 218
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
Zhanel, G. G., Lawson, C. D., Zelenitsky, S., Findlay, B., Schweizer, F., Adam, H., Walkty, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.25 · Cited by 201
Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M., Rizk, M. L., Brown, M. L., Losada, M. C., Pedley, A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-16 · Cited by 182
Management of KPC-producing Klebsiella pneumoniae infections
Bassetti, M., Giacobbe, D. R., Giamarellou, H., Viscoli, C., Daikos, G. L., Dimopoulos, G., De Rosa, F. G., Giamarellos-Bourboulis, E. J., Rossolini, G. M., Righi, E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.08.030 · Cited by 175
Self-citationGaibani, P., Campoli, C., Lewis, R. E., Volpe, S. L., Scaltriti, E., Giannella, M., Pongolini, S., Berlingeri, A., Cristini, F., Bartoletti, M., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky082 · Cited by 170
Sims, M., Mariyanovski, V., McLeroth, P., Akers, W., Lee, Y.-C., Brown, M. L., Du, J., Pedley, A., Kartsonis, N. A., & Paschke, A. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx139 · Cited by 166
Sun, D., Rubio-Aparicio, D., Nelson, K., Dudley, M. N., & Lomovskaya, O. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01694-17 · Cited by 166
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Pogue, J. M., Bonomo, R. A., & Kaye, K. S. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy576 · Cited by 164
Bassetti, M., Castaldo, N., Cattelan, A., Mussini, C., Righi, E., Tascini, C., Menichetti, F., Mastroianni, C. M., Tumbarello, M., Grossi, P., et al. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.001 · Cited by 162
Self-citationBassetti, M., Righi, E., Vena, A., Graziano, E., Russo, A., & Peghin, M. (2018) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000534 · Cited by 159
Self-citationMurepavadin: a new antibiotic class in the pipeline
Martín‐Loeches, I., Dale, G. E., & Torres, A. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1441024 · Cited by 156
Panidis, D., Markantonis, S. L., Boutzouka, E. G., Karatzas, S., & Baltopoulos, G. I. (2005) · CHEST Journal · doi:10.1378/chest.128.2.545 · Cited by 153
Moyá, B., Barceló, I. M., Bhagwat, S., Patel, M. V., Bou, G., Papp‐Wallace, K. M., Bonomo, R. A., & Oliver, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02529-16 · Cited by 145
Munita, J. M., Aitken, S. L., Miller, W. R., Pérez, F., Rosa, R. M., Shimose, L. A., Lichtenberger, P. K., Abbo, L. M., Jain, R., Nigo, M., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix014 · Cited by 142
Sader, H. S., Rhomberg, P. R., Flamm, R. K., Jones, R. N., & Castanheira, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx050 · Cited by 110
Seifert, H., Stefanik, D., Sutcliffe, J. A., & Higgins, P. G. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.022 · Cited by 108
González-Padilla, M., Torre‐Cisneros, J., Rivera-Espinar, F., Pontes-Moreno, A., López‐Cerero, L., Pascual, Á., Natera, C., Rodriguez, M., Salcedo-Leal, I., Rodríguez-López, F., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku432 · Cited by 104
Sader, H. S., Castanheira, M., Huband, M. D., Jones, R. N., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00072-17 · Cited by 79
New promising β-lactamase inhibitors for clinical use
Olsen, I. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2375-0 · Cited by 73
Bassetti, M., Welte, T., & Wunderink, R. G. (2016) · Critical Care · doi:10.1186/s13054-016-1197-5 · Cited by 63
Self-citationSader, H. S., Dale, G. E., Rhomberg, P. R., & Flamm, R. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00311-18 · Cited by 63
Crandon, J. L., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00033-15 · Cited by 57
Bono, V. D., Giacobbe, D. R., Marchese, A. E., Parisini, A., Fucile, C., Coppo, E., Marini, V., Arena, A., Molin, A., Martelli, A., et al. (2016) · Virulence · doi:10.1080/21505594.2016.1213476 · Cited by 55
Self-citationSader, H. S., Flamm, R. K., Dale, G. E., Rhomberg, P. R., & Castanheira, M. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky227 · Cited by 51
Giacobbe, D. R., Mikulska, M., & Viscoli, C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1549487 · Cited by 47
Self-citationWiskirchen, D. E., Koomanachai, P., Nicasio, A. M., Nicolau, D. P., & Kuti, J. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01253-10 · Cited by 35
Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment
Giacobbe, D. R., di Masi, A., Leboffe, L., Bono, V. D., Rossi, M., Cappiello, D., Coppo, E., Marchese, A. E., Casulli, A., Signori, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30361-5 · Cited by 32
Self-citationThe ideal patient profile for new beta-lactam/beta-lactamase inhibitors
Montravers, P., & Bassetti, M. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000490 · Cited by 32
Self-citationCastanheira, M., Williams, G. B., Jones, R. N., & Sader, H. S. (2014) · Microbial Drug Resistance · doi:10.1089/mdr.2013.0181 · Cited by 16
Cited by
Antimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024
Population genomics of Klebsiella pneumoniae
Wyres, K. L., Lam, M. M. C., & Holt, K. E. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0315-1 · Cited by 1,160
Bloodstream infections in critically ill patients: an expert statement
Timsit, J.-F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 448
Self-citationGlobal Threat of Carbapenem-Resistant Gram-Negative Bacteria
Jean, S.-S., Harnod, D., & Hsueh, P.-R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.823684 · Cited by 366
Metadata
- Authors
- Bassetti, M., Peghin, M., Vena, A., & Giacobbe, D. R.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2019-04-16
- Volume
- 6
- Pages
- 74-74
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2924739878
- Cited by
- 326
- References
- 59
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.